The Latest Oncology Journal Articles
The latest oncology journal articles in a single view, including medical oncology and radiation oncology. Articles are selected from the leading medical journals, including Journal of Clinical Oncology, Annals of Oncology and The Lancet Oncology.
You can navigate to the ‘Drugs’ section using the menu bar at the top of the page to find the latest research articles relating to specific oncology treatments.
For the latest articles relating to specific tumour / cancer types use the links in the list below:
- Breast cancer
- Gastrointestinal cancer
- Gynaecological cancer
- Haemato-oncology
- Lung cancer
- Skin cancer
- Urologic oncology
Latest Oncology Articles
- Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.Patients with gestational trophoblastic neoplasia who have an International Federation of Gynaecology […]
- Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.The addition of camrelizumab to gemcitabine and cisplatin showed promising activity as […]
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and […]
- Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study.The majority of young adults with Hodgkin lymphoma (HL) are cured, but […]
- Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive […]
- Acquired Resistance to KRASG12C Inhibition in Cancer.Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising […]
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen […]
- Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).The prospective, randomized AHL2011 trial demonstrated that the use of the doxorubicin, […]
- Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.CD19-targeted chimeric antigen receptor (CAR)-modified T cells demonstrate unprecedented responses in B-cell […]
- Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged […]
- Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.Induction therapy is a critical component of the therapy of high-risk neuroblastoma. […]
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy […]
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), […]
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.China has a high burden of hepatocellular carcinoma, and hepatitis B virus […]
- Deep learning for diagnosis and survival prediction in soft tissue sarcoma.Clinical management of soft tissue sarcoma (STS) is particularly challenging. Here, we […]
- Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab […]
- Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase […]
- Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study.The phase III CHAARTED trial established upfront androgen deprivation therapy (ADT) plus […]
- Mortgage Lending Bias and Breast Cancer Survival Among Older Women in the United States.The objective was to examine the relationship between contemporary redlining (mortgage lending […]
- Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.Conventional external beam radiotherapy is the standard palliative treatment for spinal metastases; […]
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Oncogenic alterations in RET have been identified in multiple tumour types, including […]
- Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for […]
- Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.The Oncology Grand Rounds series is designed to place original reports published […]
- Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).To analyze the effect of radiation dose escalation to the primary tumor […]
- Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.This study assessed the joint association of pathogenic variants (PVs) in breast […]
- Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death.Adjuvant compared with early salvage radiation therapy (sRT) following radical prostatectomy (RP) […]
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced […]
- Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C).Variation in risk of adverse clinical outcomes in patients with cancer and […]
- The effect of non-AIDS-defining cancers on people living with HIV.Non-AIDS-defining cancers are a growing source of morbidity for people with HIV […]
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical […]
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine […]
- Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.Arsenic combined with all-trans retinoic acid (ATRA) is the standard of care […]
- Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.Although NRG1 fusions are oncogenic drivers across multiple tumor types including lung […]
- Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.To evaluate the use of early assessment of chemotherapy responsiveness by positron […]
- Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.Understanding patients’ experience of cancer treatment is important. We aimed to evaluate […]
- Impact of COVID-19 on cancer care in India: a cohort study.The COVID-19 pandemic has disrupted health-care systems, leading to concerns about its […]
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive […]
- Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bladder […]
- Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study.Colorectal cancer screening programmes and uptake vary substantially across Europe. We aimed […]
- Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.Women treated with chest radiation for childhood cancer have one of the […]
- Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children’s Oncology Group Trial AAML0531.We investigated the impact of the CD33-targeted agent gemtuzumab ozogamicin (GO) on […]
- The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer.There is no universally accepted instrument to use as a validated surrogate […]
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving […]
- Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: Secondary analysis of a prospective randomized trial.Nutritional support in patients with cancer aims at improving quality of life. […]
- Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ.Ductal carcinoma in situ (DCIS) accounts for 20% of breast cancer cases […]
- Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.The purpose of this phase II study was to evaluate hyperthermic intraperitoneal […]
- Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.Several de-escalation approaches are under investigation in patients with HER2-positive, early-stage breast […]
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.Previous phase 2 trials of neoadjuvant anti-PD-1 or anti-PD-L1 monotherapy in patients […]
- Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, […]
- Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 […]
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.The CATNON trial investigated the addition of concurrent, adjuvant, and both current […]
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.Before February, 2021, there was no standard treatment regimen for locally advanced […]
- Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial.Patients with cancer experience high rates of morbidity and unplanned health care […]
- Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).Breast cancer is increasingly prevalent in older adults and is a substantial […]
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce […]
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in […]
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do […]
- Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are active as single agents […]
- Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).The combination of gemcitabine and cisplatin (GC) is a standard therapy for […]
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.Effective treatment options are limited for patients with advanced (metastatic or unresectable) […]